For patients undergoing kidney transplantation, treatment with the anti-rejection drug sirolimus may lead to an increased risk of diabetes, reports a new study. The results suggested a higher rate of post-transplant diabetes among patients treated with sirolimus, compared to other anti-rejection drugs. Depending on which additional drugs they received, diabetes risk was 36 to 66 percent higher for patients receiving sirolimus.
- Anti-rejection drug may increase risk of diabetes after kidney transplantThu, 22 May 2008, 14:22:04 EDT
- Drug may prolong organ life in noncompliant kidney transplant patientsSat, 31 May 2008, 3:42:36 EDT
- Gene mutation increases drug toxicity, rejection risk in pediatric kidney transplantsWed, 18 Feb 2009, 9:56:22 EST
- Best post-transplant drug regimen identified for patients with new kidneysFri, 29 Jul 2011, 0:35:27 EDT
- Gene pattern may identify kidney transplant recipients who don't need life-long anti-rejection drugsMon, 24 May 2010, 17:36:19 EDT